ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Panel Says Tamoxifen Remains Standard for Preventing Breast Cancer

May 24, 2002

Congress Provides 7% Increase For NIH, 6.6% for NCI, In FY98 Appropriation

November 14, 1997

DCE Board Approve Concepts For Contract Recompetitions

November 23, 1984

Diane Fink Accepts VP Job With ACS

April 3, 1981

Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work.

May 7, 2004

Civin Moves From Hopkins To Maryland To Direct Stem Cell Medicine Center

January 9, 2009